BridgeBio Oncology Therapeutics Inc. (BBOT) Research

BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

Market snapshot

Symbol
BBOT
Price
$7.56
Day change
-1.56%
Market cap
$605.6M
P/E ratio
-1.53x
52-week range
7-14.87
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$22.00

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • Kodiak Sciences Inc. (KOD)
  • Mind Medicine (MindMed) Inc. (MNMD)
  • Nurix Therapeutics, Inc. (NRIX)
  • Oculis Holding AG (OCS)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • Septerna, Inc. (SEPN)
  • Tango Therapeutics, Inc. (TNGX)

Recent insider activity

  • Tipirneni Praveen P. — A-Award (31675 shares) on 2026-06-16
  • MCCORMICK FRANK — A-Award (31675 shares) on 2026-06-16
  • Lebowitz Peter F — A-Award (7289 shares) on 2026-06-16
  • Kelleher Raymond J. — A-Award (31675 shares) on 2026-06-16
  • Chen Bihua — A-Award (31675 shares) on 2026-06-16

Open BridgeBio Oncology Therapeutics Inc. (BBOT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.